Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agile Therapeutics Inc AGRX

Alternate Symbol(s):  AGXRW

Healthcare
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a... see more

Recent & Breaking News (OTCPK:AGRX)

Agile Therapeutics to Present Additional Phase 3 Data at the North American Forum on Family Planning Annual Meeting

GlobeNewswire September 28, 2017

Agile Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 14, 2017

Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for Reproductive Medicine

GlobeNewswire September 7, 2017

Agile Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

GlobeNewswire August 22, 2017

Agile Therapeutics to Present at Liolios 6th Annual Gateway Conference

GlobeNewswire August 16, 2017

Agile Therapeutics Announces Pricing of Its Public Offering of Common Stock

GlobeNewswire August 3, 2017

Agile Therapeutics Announces Proposed Offering of Common Stock

GlobeNewswire August 2, 2017

Agile Therapeutics Reports Second Quarter 2017 Financial Results

GlobeNewswire July 28, 2017

Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®

GlobeNewswire July 27, 2017

Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla®

GlobeNewswire June 27, 2017

22 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  June 16, 2017

Agile Therapeutics Reports First Quarter 2017 Financial Results

GlobeNewswire May 8, 2017

Agile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla® at ACOG 2017

GlobeNewswire May 6, 2017

Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists

GlobeNewswire May 3, 2017

Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Women’s Health

GlobeNewswire April 27, 2017

Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA

GlobeNewswire April 11, 2017

Generic Drugs Stocks on Investors' Radar -- Diplomat Pharma, Momenta Pharma, Agile Therapeutics, and Sophiris Bio

PR Newswire April 7, 2017

15 Biggest Mid-Day Losers For Monday

Benzinga.com  March 20, 2017

15 Biggest Mid-Day Gainers For Friday

Benzinga.com  March 17, 2017

Agile Therapeutics Announces a Poster Presentation of its SECURE Phase 3 Study at the Contraceptive Technology 2017 Conference

GlobeNewswire March 16, 2017